Resource Type

Journal Article 1

Year

2022 1

Keywords

obesity 1

semaglutide 1

type 2 diabetes 1

Search scope:

排序： Display mode:

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 17-24 doi: 10.1007/s11684-021-0873-2

Abstract: Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretionThis review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes

Keywords： semaglutide     type 2 diabetes     obesity    

HTML PDF Collect

Title Author Date Type Operation

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

Journal Article